Have a confidential tip for our reporters? You understand and agree that Muddy Waters Capital does not have any investment advisory relationship with you or does not owe fiduciary duties to you. The research and reports presented on this website express the opinion of the applicable Muddy Waters Entity only. PeptiDream touts its 19 major partnerships and 101 discovery programs, but half of its partnerships are … PeptiDream fell as much as 5.5% in Tokyo trading Thursday after the short seller questioned the level of activity at the company’s drug development partnerships with pharmaceutical companies. “But we believe the coolness of PeptiDream’s technology amounts to at best a very small business opportunity.”, Read more: Failed Guitarist Seeking Life’s Roots Makes $3 Billion Drug Firm. We forecast PeptiDream will have at most one drug commercialized by 2027, versus investor expectations of eight to 15 by then. The opinions, information and reports set forth herein are solely attributable to the applicable Muddy Waters Entity and are not attributable to any Muddy Waters Related Person (defined below) (other than the applicable Muddy Waters Entity). The biotech firm, based in Kanagawa outside Tokyo, is developing a peptide system to facilitate the discovery and testing of new drugs in a range of diseases from cancer to neurological conditions. You further agree that any dispute between you and Muddy Waters Research and its affiliates arising from or related to this report and / or the Muddy Waters Research website or viewing the material hereon shall be governed by the laws of the State of California, without regard to any conflict of law provisions. Joyy Inc. MW is Short Joyy Inc. (YY US) While trawling the sewers of the world’s capital markets over the past 10 years, irony has never been in short supply. The company said its 101 programs are all active programs and that they don’t include dead or dormant ones. Latest Reports. We believe this comparison would be more relevant to PeptiDream if the Jaguar were missing its wheels. You accept all risks in relying on the information on this website. Muddy Waters Research is affiliated with Muddy Waters Capital. If you are in the United Kingdom, you confirm that you are accessing research and materials as or on behalf of: (a) an investment professional falling within Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “FPO”); or (b) high net worth entity falling within Article 49 of the FPO (each a “Permitted Recipient”). You (or any person you are acting as agent for) agree to hold harmless Muddy Waters Research, Muddy Waters Capital and its affiliates and related parties, including, but not limited to any principals, officers, directors, employees, members, clients, investors, consultants and agents (collectively, the “Muddy Waters Related Persons”) for any direct or indirect losses (including trading losses) attributable to any information on this website or in a research report. Muddy Waters peels back the layers, often built up by seemingly respected but sycophantic law firms, auditors, and venal managements. By downloading from, or viewing material on this website, you agree to the following Terms of Use. Muddy Waters said it’s short Japanese biotech stock PeptiDream Inc., sending the company’s shares sliding. All expressions of opinion are subject to change without notice, and neither Muddy Waters Research nor Muddy Waters Capital undertakes to update or supplement any reports or any of the information, analysis and opinion contained in them. Giving investment advice requires knowledge of your financial situation, investment objectives, and risk tolerance, and Muddy Waters Capital has no such knowledge about you. Muddy Waters Research, Muddy Waters Capital and/or the Muddy Waters Related Persons intend to continue transacting in the securities of Covered Issuers for an indefinite period after an initial report on a Covered Person, and such person may be long, short, or neutral at any time hereafter regardless of their initial position and views as stated in the research report published by Muddy Waters Research or Muddy Waters Capital. However, such information is presented “as is,” without warranty of any kind, whether express or implied. Reports are based on generally available information, field research, inferences and deductions through the applicable Muddy Waters Entity’s due diligence and analytical process. To even remotely justify investor expectations, PeptiDream would likely need to succeed in meeting drug development milestones at rates many times industry norms. You represent that you have sufficient investment sophistication to critically assess the information, analysis and opinion on this website. You agree that use of the research on this website is at your own risk. PeptiDream has “really cool” technology, Muddy Waters said in the report. You agree that regardless of any statute or law to the contrary, any claim or cause of action arising out of or related to this website or the material on this website must be filed within one (1) year after the occurrence of the alleged harm that gave rise to such claim or cause of action, or such claim or cause of action be forever barred. Sign up for our mailing list and receive research reports and other related news and updates from Muddy Waters Research. In relation to the United Kingdom, the research and materials on this website are being issued only to, and are directed only at, persons who are Permitted Recipients and, without prejudice to any other restrictions or warnings set out in these Terms of Use, persons who are not Permitted Recipients must not act or rely on the information contained in any of the research or materials on this website. If any provision of these Terms of Use is found by a court of competent jurisdiction to be invalid, the parties nevertheless agree that the court should endeavor to give effect to the parties’ intentions as reflected in the provision and rule that the other provisions of these Terms of Use remain in full force and effect, in particular as to this governing law and jurisdiction provision. OPEC Faces Seismic Demand Split as Cartel Plots Next Move, Zappos Founder Tony Hsieh Dies at 46; Bezos Mourns Untimely Loss, Vaccines Awaited; Hong Kong Suspends Classes: Virus Update, Tesla FOMO Fires Up Wall Street’s $300 Billion Custom-Index Boom, Trump Nominates a Top Bank Regulator as Biden Starts Transition. PeptiDream has really cool technology – it can put trillions of different peptides in a single test tube! Click to share on Twitter (Opens in new window), Click to share on Facebook (Opens in new window), Click to share on LinkedIn (Opens in new window), Click to share on Reddit (Opens in new window), Click to email this to a friend (Opens in new window), Click to share on Tumblr (Opens in new window), Click to share on Pocket (Opens in new window), Click to share on Telegram (Opens in new window).